Ascendis Pharma Authorizes $400 Million Share Buyback
On September 14, Ascendis Pharma A/S (NASDAQ:ASND) announced a share buyback program of up to $400 million. This follows strong financial performance in the first half of 2026, including product revenue rising by 105% year-over-year to €315 million and an operating profit of €220 million—up from a loss previously. The company's cash position also improved significantly, with €812 million on hand as of June 30. This financial strength is attributed in part to the sale of a priority review voucher for €158 million and the conversion of $575 million in convertible notes into equity. However, despite these gains, YORVIPATH remains the dominant revenue driver at €252 million out of total product sales. The buyback is not binding on Ascendis; it can be modified or canceled based on market conditions and share price. Institutional interest has increased slightly with 49 hedge funds holding shares in Q3, but short positions remain significant at 7.59% of the float.
Tickers: $ASND
Topics: balance sheet management cash flow improvement stock repurchase